1. Home
  2. SNES vs CLGN Comparison

SNES vs CLGN Comparison

Compare SNES & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SenesTech Inc.

SNES

SenesTech Inc.

N/A

Current Price

$1.29

Market Cap

5.9M

Sector

Industrials

ML Signal

N/A

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

N/A

Current Price

$4.08

Market Cap

5.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNES
CLGN
Founded
2004
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Agricultural Chemicals
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.2M
IPO Year
2016
2015

Fundamental Metrics

Financial Performance
Metric
SNES
CLGN
Price
$1.29
$4.08
Analyst Decision
Analyst Count
0
0
Target Price
★ $7.50
N/A
AVG Volume (30 Days)
★ 2.5M
47.1K
Earning Date
11-09-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 77.99
N/A
EPS
N/A
★ N/A
Revenue
★ $600,000.00
N/A
Revenue This Year
$57.09
N/A
Revenue Next Year
$50.16
$25.00
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 132.56
N/A
52 Week Low
$0.55
$0.26
52 Week High
$3.61
$4.78

Technical Indicators

Market Signals
Indicator
SNES
CLGN
Relative Strength Index (RSI) 65.36 58.91
Support Level $0.59 $0.34
Resistance Level $1.81 $4.62
Average True Range (ATR) 0.13 0.33
MACD 0.04 -0.01
Stochastic Oscillator 86.14 56.89

Price Performance

Historical Comparison
SNES
CLGN

About SNES SenesTech Inc.

SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company has developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Its current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: